Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.935
-0.195 (-3.81%)
At close: Mar 3, 2026, 4:00 PM EST
4.920
-0.015 (-0.30%)
After-hours: Mar 3, 2026, 4:10 PM EST
Molecular Partners AG Employees
Molecular Partners AG had 153 employees as of June 30, 2025. The number of employees decreased by 6 or -3.47% since the number was reported on December 31, 2024.
Employees
153
Change
-6
Growth
-3.47%
Revenue / Employee
n/a
Profits / Employee
-$493,725
Market Cap
184.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 153 | -6 | -3.47% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Nkarta | 105 |
| Vaxart | 105 |
| Tonix Pharmaceuticals Holding | 81 |
| Compugen | 74 |
| SAB Biotherapeutics | 63 |
| Galectin Therapeutics | 15 |
| Sagimet Biosciences | 14 |
| Tiziana Life Sciences | 9 |
MOLN News
- 6 days ago - Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript - Seeking Alpha
- 4 weeks ago - Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 - GlobeNewsWire
- 6 weeks ago - Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 3 months ago - Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript - Seeking Alpha
- 4 months ago - Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action - GlobeNewsWire